Nitric Oxide Services has access to proprietary nitric oxide-donor compounds, synthesis facilities and analytical methods and instrumentation which provides a comprehensive platform to meet the challenge of any NO-based research project from inception to completion. To learn more about our capabilities, click below:
We are dedicated to the research and development of Nitric Oxide (NO). Our clients have included the National Cancer Institute (NCI), major medical institutions, universities, Fortune 500 companies, and biotech start-ups.
BNOAT Oncology, Inc. is a start-up company of the University of Akron Research Foundation which has the exclusive license to develop US Patent 5,936,082 which pertains to a drug which delivers nitric oxide (nitrosylcobalamin, NO-Cbl) to cells by a cell surface receptor known as CD320. NO-Cbl has demonstrated preclinical efficacy as an anti tumor agent against human, canine and feline cancers.
dedicated to the research and development of Nitric oxide